Health AI Startup Biofourmis Hits $1.3 Billion Valuation With Series D Funding

Biofourmis, a startup developing digital therapeutics and artificial intelligence to remotely monitor patients, said its valuation hit $1.3 billion after raising a $300 million Series D funding round led by General Atlantic. The Boston-based company said CVS Health joined the round, along with existing investors, and also announced Omar Ishrak, chairperson of Intel and former CEO of Medtronic, will chair its board. Biofourmis had previously raised a $100 million round in September 2020 led by SoftBank Investment Advisers at an undisclosed valuation. This Series D round brings the company's total funding to $445 million. Originally based in Singapore, Biofourmis moved its headquarters to the United States in 2019.